Jan Astermark
21 – 30 of 191
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
- Contribution to journal › Article
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
- Contribution to journal › Article
-
Mark
Considerations for shared decision management in previously untreated patients with hemophilia A or B
- Contribution to journal › Scientific review
-
Mark
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice
- Contribution to journal › Article
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
- Contribution to journal › Scientific review
-
Mark
High use of pain, depression, and anxiety drugs in hemophilia : more than 3000 people with hemophilia in an 11-year Nordic registry study
- Contribution to journal › Article
-
Mark
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context
- Contribution to journal › Article
- 2022
-
Mark
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B : Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires
- Contribution to journal › Article
-
Mark
New Inhibitors in the Ageing Population : A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia
- Contribution to journal › Article
-
Mark
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins : Real-world experience in the Nordic countries
- Contribution to journal › Article
